Covidien Announces Interim Data Showing Single Incision Gall Bladder Surgery with SILS(TM) Port Associated with Improved Cosmetic Outcome Compared to Four-Port Laparoscopic Approach

NORTH HAVEN, Conn.--(BUSINESS WIRE)--Covidien (NYSE: COV), a leading global provider of healthcare products, today announced interim results of its multicenter, international, prospective SILS™ Port laparoscopic cholecystectomy (removal of the gall bladder) post-market clinical study.